|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase I trialinvolving the pharmacodynamic ( PD) study of circulatingtumour cells, of CP - 7 5 1 8 7 1 , a monoclonal antibody againstthe insulin - like growth factor 1 receptor ( IGF -1R ),with docetaxel ( D) in patients with advanced cancer显示文摘 | ATTARD G FONG P C MOLIFE R | | JC lin Oncol0，22，9： | 1 |
| 2 | A phase Ⅰ dose escalation study of AT9283,a small molecule inhibitor of aurora kinases in patients with advanced solid malignancies显示文摘 | ARKENAU H T PLUMMER R MOLIFE L R | 2012 | Ann Oncol2012，23，5： | 1 |
| 3 | Economic Outcomes for Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Receiving Prasugrel or Ticagrelor:A Retrospective US Hospital Database Analysis显示文摘 | Molife C Frech-Tamas F Effron M B | 2014 | Circulation:Cardiovascular Quality and Outcomes2014，7，1： | 1 |
| 4 | FGF Receptor Inhibitors: Role in Cancer Therapy显示文摘 | Gennaro Daniele Jesus Corral L. Rhoda Molife Johann S. Bono | 2012 | Current Oncology Reports2012，，2： | 1 |
| 5 | 显示文摘 | | 1995 | Tedrahedron Lett1995，36，52： | 1 |
| 6 | Belinostat: clinical applications in solid tumors and lymphoma显示文摘 | Molife LR De Bono JS | 2011 | Expert Opin lnvestig Drugs2011，20，12： | 1 |
| 7 | A further break-through in biphasic, rhodium-catalyzed hydroformylation: the use of Per(2,6-di-O-methyl)-β-cyclodextrin as inverse phase transfer catalyst 显示文摘 | Molifer E Tilloy S Fremy G | 1995 | Tedrahedron Lett1995，36，52： | 1 |
| 8 | A phase I pharmaco-' kinetic and pharmacodynamic study of TKI258, an ora, 1 muhitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors 显示文摘 | Sarker D Molife R Evans T R J | 2008 | Clin Cancer Res2008，14，7： | 1 |
| 9 | A phaseⅠstudy of the safety and pharmacokinetics of the histonedeacetylase inhibitor belinostat administered in combina-tion with carboplatin and/or paclitaxel in patients with sol-id tumours显示文摘 | Lassen U Molife LR Sorensen M | 2010 | Br J Cancer2010，103，1： | 1 |
| 10 | predictive biomarkers for targeting insulin-like growth factor-1 (IGF-1)receptor显示文摘 | Carden CP Molife LR de Bono JS | | 0，，08： | 1 |
| 11 | A pha- se I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies 显示文摘 | ARKENAU H T PLUMMER R MOLIFE L R | 2012 | Ann Onco12012，23，5： | 1 |
| 12 | A phase Ⅰ pharmacokinetic and pharmacodynamic study of TKI258, an oral, muhitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors 显示文摘 | SARKER D MOLIFE R EVANS TRJ | 2008 | Clin Cancer Res2008，14，7： | 1 |
| 13 | A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709,an oral multi-targeted growth inhibitor (MTGI),in patients with advanced solid tumours显示文摘 | Scott EN Thomas AL Molife LR | 2009 | Cancer Chemother Pharmacol2009，64，2： | 1 |
| 14 | Phase 1 trial of the oral AKT inhibitor MN-2206 plus carboplatin/paclitaxel, do- cetaxel, or erlotinib in patients with advanced solid tumors显示文摘 | Molife LR Yan L Vitfelll Rasmussen J | 2014 | J H ematol Oncol2014，7，1： | 1 |
| 15 | Targeting cell cyclekinases and kineains in anlicancer drug development 显示文摘 | YapTA Molife LR Blagden SP | 2007 | Expert Opin Drug Discov2007，2，53： | 1 |
| 16 | Phase II study of eribu- lin mesylate( E7389 )in patients with metastatic castration -resistant prostate cancer stratified by prior taxane therapy 显示文摘 | de Bonn J S Molife L R Sonpavde G | 2012 | Annals of On- cology2012，23，5： | 1 |
| 17 | Safety,pharmacokinet-ics,and preliminary activity of the anti-GF-1R antibody figitu-mumab (CP-51,871) in patients with sarcoma and Ewing's sarcoma:a phase 1 expansion cohort study显示文摘 | Olmos D Postel-Vinay S Molife LR | 2010 | Lancet Oncol2010，11，2： | 1 |
| 18 | Adjuvant therapy of malignant mlanoma显示文摘 | Molife R Hancock BW | 2002 | Crit Rev Oncol Hematol2002，44，： | 1 |
| 19 | Adjuvant therapy of malignant melanoma 显示文摘 | Molife R Hancock BW | 2002 | Crit Rev Oncol Hematol2002，44，1： | 1 |
| 20 | Phase , two-stage, single- arm trial of the bistone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC) 显示文摘 | Molife LR Attard G Fong PC | 2010 | Ann Oncol2010，21，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员